Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Reiterates Outperform on Varonis Systems, Maintains $31 Price Target

RBC Capital analyst Matthew Hedberg reiterates Varonis Systems (NASDAQ:VRNS) with a Outperform and maintains $31 price target.

byBenzinga Newsdesk

March 15, 2023

1 minute read

RBC Capital analyst Matthew Hedberg reiterates Varonis Systems (NASDAQ:VRNS) with a Outperform and maintains $31 price target.

Microsoft-Backed OpenAI Addresses Bias Concerns, Moves To Allow User Customization Of ChatGPT

By Ananya Gairola

Today, 3:55 AM

Microsoft Corporation (NASDAQ:MSFT)-backed OpenAI says it is developing an upgrade to its chatbot, which would allow users to…

MSFT

Stock Wars: Kohl’s Vs. Ross Stores

By Phil Hall

Today, 3:55 AM

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.

KSS

Flower Foods Boosts Dividend & Buyback – Read More For Details

By Shivani Kumaresan

Today, 3:55 AM

Flower Foods Inc (NYSE:FLO) board of directors has declared a 4.8% increase in the quarterly dividend to $0.22 per share. The…

FLO

Zynerba Pharmaceuticals Reveals Lower Net Loss For Q4 And Full Year 2021

By Nina Zdinjak

Today, 3:55 AM

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021.

ZYNE

RBC Capital Reiterates Outperform on Varonis Systems, Maintains $31 Price Target

Related Posts

Microsoft-Backed OpenAI Addresses Bias Concerns, Moves To Allow User Customization Of ChatGPT

Stock Wars: Kohl’s Vs. Ross Stores

Flower Foods Boosts Dividend & Buyback – Read More For Details

Zynerba Pharmaceuticals Reveals Lower Net Loss For Q4 And Full Year 2021